SLS Stock Surges After-Hours: Sellas Says 'Transformative' Phase 3 AML Results Are Coming This Month

Shares of Sellas Life Sciences (SLS) surged 17% in after-hours trading on Thursday after the company said that its key leukemia trial results are expected this month, with its CEO pointing to the treatment’s potential to become a “transformative” immunotherapy if successful.SLS stock fell nearly 5…